Researchers at the University at Buffalo developed an injectable hydrogel platform on August 19, 2026, to transform osteoarthritis treatment by forming a lubricating semi-solid depot inside joints at body temperature after a single minimally invasive injection. The author highlights how this biocompatible system overcomes traditional treatment barriers where small-molecule drugs and biologics disappear quickly from synovial fluid, allowing drug-loaded nanocarriers to remain in place and release medication gradually over several weeks. The essence of this innovation lies in its dual function as a sustained-release drug delivery system and a viscosupplement, featuring high drug-loading capacity for poorly water-soluble compounds and utilizing materials with prior regulatory acceptance. Practical applications include reducing the need for repeated invasive joint injections, limiting systemic side effects, and targeting underlying biological mechanisms like chronic inflammation and cellular senescence using disease-modifying therapies such as a SIRT6 activator.
